ADPT · Adaptive Biotechnologies

The thesis

Adaptive Biotechnologies is more likely than not to beat the S&P 500 over the next three months. Demand for its clonoSEQ blood-cancer test is growing faster than the price of the shares assumes. Tests rose 46% from a year earlier in the third quarter of 2026, and full-year minimal residual disease (MRD) revenue guidance rose to $276–286 million on 4 November 2026. The open question is price per test. Medicare's final 2027 laboratory rates, which the Centers for Medicare & Medicaid Services (CMS) expects to publish in November 2026, settle it. The fourth-quarter report then tests the guidance.

The rating is Medium because volume, guidance and cash flow all improved in the 4 November 2026 report, while the Medicare rate and the reliance on one pharma payment are unresolved. Guggenheim kept its Buy rating and raised its target to $34 on 10 November 2026, per Benzinga. The shares closed at $29.48 on 12 November 2026, after an intraday 52-week high of $32.21 on 11 November 2026.

Management presents at the Jefferies Global Healthcare Conference in London on 18 November 2026 and holds a fireside chat at the Piper Sandler Healthcare Conference on 2 December 2026, per a company release dated 10 November 2026. Both fall around the expected CMS decision, so management can be asked about the final clonoSEQ rate in public.

Bullish and bearish views on Adaptive Biotechnologies Corporation

The bull case on Adaptive Biotechnologies Corporation (ADPT), in brief: volume growth sped up again. The bear case: the Medicare rate error is unresolved.

Bull case

• Volume growth sped up again. The company delivered 39,587 clonoSEQ tests in the third quarter, up 46% from a year earlier and 10% from the previous quarter, per the 4 November 2026 release and call. Blood-based testing made up 51% of volume.
• Guidance rose for the second straight quarter. MRD revenue guidance moved to $276–286 million on 4 November 2026, from $268–278 million set on 29 July 2026. Chief Financial Officer Kyle Piskel lifted expected 2026 clinical volume growth to about 42% from 38–40%.
• The company paid its own way in the third quarter. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was $14.3 million and free cash flow was $7.7 million, per the 4 November 2026 release. The MRD segment alone produced $15.1 million of adjusted EBITDA.
• Cash is ample. Cash and marketable securities were $400.2 million on 30 September 2026, per the third-quarter release, up from $371.7 million on 30 June 2026.
• Guidelines now cover maintenance testing. The National Comprehensive Cancer Network (NCCN) set out a dedicated MRD framework for multiple myeloma on 17 September 2026, including annual testing during maintenance, per the third-quarter release. Adaptive has asked MolDX, the Medicare contractor program that reviews molecular tests, to cover an additional maintenance-testing bundle.
• Drug-company demand is growing. The MRD pharma backlog was about $270 million, up 34% from a year earlier, across 191 active studies, per the 4 November 2026 call.
• Analysts are still raising targets after the report. Guggenheim raised its target to $34 on 10 November 2026, per Benzinga. MarketBeat's consensus target was $30.06 on 6 November 2026, with six Buy, one Hold and one Sell rating.

Bear case

• The Medicare rate error is unresolved. On the 4 November 2026 call the CFO said erroneous data had been submitted on the clonoSEQ Proprietary Laboratory Analysis (PLA) code during preliminary rate-setting. He expects a correction and gave no figure for its effect. HFMA reported on 22 September 2026 that most PLA tests fall outside the 15% annual cap on cuts for 2027–2029.
• Third-quarter profit leaned on Pfizer. Immune Medicine revenue was $11.3 million, mostly from a Pfizer target-discovery agreement, and carries no guidance. Management expects no GAAP profit for 2026. The nine-month 2026 net loss attributable to Adaptive was $56.9 million, and adjusted loss per share of $0.13 missed the $0.10 estimate, per Benzinga on 4 November 2026.
• Total revenue fell from a year earlier. Third-quarter revenue was $83.9 million against $93.97 million a year earlier, per the 10-Q filed 4 November 2026, because Genentech revenue dropped out. Excluding Genentech, revenue rose 39%.
• Price per test is far from the goal. US average selling price was $1,380 in the third quarter, up 3% from a year earlier, per the 4 November 2026 call. The long-term goal is $1,700–1,800.
• The President keeps selling. SEC Form 4 filings show Julie Rubinstein, President and Chief Operating Officer, exercising options at $12.14 and selling 35,643 shares in each filing from 13 October to 6 November 2026. The 10 November 2026 filing reports 23,762 more shares sold at an average $29.82 on 9 November 2026 and 10 November 2026. All sales ran under a Rule 10b5-1 plan.
• A competitor is testing against clonoSEQ. On 29 October 2026 Telo Genomics expanded its comparative evaluation of the blood-based TELO-MRD assay against clonoSEQ, per company news.

Price setup

The shares closed at $29.48 on 12 November 2026, 8.5% below the intraday 52-week high of $32.21 set on 11 November 2026. That day they closed at $29.94, so the session gave back most of its intraday gain. The highest recent close was $30.26 on 9 November 2026.

The move after the report came in two steps. The close was $26.83 on 5 November 2026 and $27.98 on 6 November 2026, then $30.26 on 9 November 2026. Since then the shares have held between $29.36 and $29.94 at the close.

In adjusted daily closes the 50-day moving average was $26.82 and the 200-day moving average $20.03 on 12 November 2026. The shares are 19.2% higher than the $24.74 close of 14 August 2026. The 52-week closing low was $12.41 on 27 March 2026, so the price has more than doubled in under eight months. A close back under the 50-day average would put the shares at prices first seen in mid-October, before the report.

The shares trade close to the post-report targets: Guggenheim's $34 and MarketBeat's $30.06 consensus. There is $345 million of zero-coupon convertible notes due 2031, and noteholder hedging can add short selling.

Catalysts ahead

• 18 November 2026: Presentation at the Jefferies Global Healthcare Conference in London, 4:00 p.m. GMT. First public management appearance since the third-quarter report; shows whether the company has any update on the clonoSEQ Medicare rate correction or fourth-quarter volume.
• ~30 November 2026 (est.): CMS final 2027 Clinical Laboratory Fee Schedule rates. Shows whether the erroneous clonoSEQ data was corrected before rates were set, and whether the price-per-test case carries a new problem from 1 January 2027.
• 2 December 2026: Fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York, 4:00 p.m. Eastern Time. Likely the first chance for management to quantify the final Medicare rate's effect on 2027 revenue in public.
• 12 December 2026: American Society of Hematology annual meeting opens in New Orleans, running through 15 December 2026. Several diffuse large B-cell lymphoma studies read out there, which bears on the fastest-growing part of test volume.
• ~31 December 2026 (est.): Year-end commitment to announce the path for separating Immune Medicine. The only dated commitment on the separation; if it passes with no named form, the shares stay valued as one combined business.
• ~15 February 2027 (est.): Fourth-quarter 2026 report; the company has not set a date. Tests the $276–286 million MRD guidance and shows whether adjusted EBITDA stays positive without a large Pfizer payment.

What would change the view

A weekly close below $25.00, which would put the shares back at mid-October prices and erase the gain since the 4 November 2026 third-quarter report. Full-year 2026 MRD revenue below the $276 million low end of guidance would also break the case.

The risks this note tracks, each with what would confirm it:

• Final Medicare rates rely on the erroneous clonoSEQ data, with no 15% cap to bound the cut. Confirmed by: a published final 2027 clonoSEQ rate below the current rate, with management reporting a revenue effect at the 18 November 2026 or 2 December 2026 conference or in a release.
• Average selling price stays well short of the $1,700–1,800 goal as Medicare's share of testing grows. Confirmed by: US average selling price at or below the $1,380 of the third quarter of 2026 in the fourth-quarter report, or a MolDX decision that denies the maintenance-testing bundle.
• Third-quarter profitability proves dependent on Pfizer revenue. Confirmed by: negative company-wide adjusted EBITDA or free cash flow in the fourth quarter of 2026 alongside a sharp fall in Immune Medicine revenue.
• Volume growth slows before the NCCN guideline adds orders. Confirmed by: fourth-quarter 2026 clonoSEQ tests below the 39,587 reported for the third quarter, or full-year clinical volume growth below the roughly 42% management now expects.
• The share price has caught up with analyst targets after the report. Confirmed by: covering firms cutting ratings to Hold or below, or moving targets under the 12 November 2026 close of $29.48.
• Competing blood-cancer MRD tests win comparative evaluations. Confirmed by: published head-to-head data, such as from Telo Genomics' evaluation expanded 29 October 2026, showing equivalence along with guideline or payer adoption.

What it trades with

The shares trade on events specific to Adaptive: clonoSEQ volumes, Medicare pricing and pharma milestones. The broad market matters less. The closest common driver is the CMS laboratory rate decision, which hits other molecular-diagnostics labs billing PLA and sequencing codes at the same time. The Immune Medicine separation is a corporate event with no direct peer link.